Jefferies analyst Biren Amin says Alkermes last night announced positive data from the ENLIGHTEN-1 study testing ALKS-3831 patients with schizophrenia for four weeks. The study demonstrated a numerically better improvement in PANSS compared to olanzapine and statistical significant improvements versus placebo in PANSS and CIGS, Amin tells investors in a research note. He adds, however, that the more important data to assess clinical relevance will report later this year and the weight gain data will report in the first half of 2018. The analyst keeps a Buy rating on Alkermes with a $69 price target.